arrow
A

Arvind Dasari

The University of Texas MD Anderson Cancer Center
H指数:43
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fruquintinib in less pretreated patients: multivariate profile-matching analysis of FRESCO-2 to FRESCO

fruquintinib 在较少预治疗患者中的研究:FRESCO-2 与 FRESCO 的多变量配型匹配分析

2025-07-130
OA
Utilizing Patient Input in Rectal Cancer Trial Design

利用患者反馈进行直肠癌试验设计

2025-03-190
PRE
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2

fruquintinib联合最佳支持治疗用于转移性结直肠癌患者的质量调整生存:FRESCO-2研究的结果

2025-03-010
OAAI
Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial

癌症相关性疲劳的体力活动与地塞米松治疗:一项初步的安慰剂对照、随机、双盲试验

2025-01-010
PRE
Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume
2024-05-102
OAAI
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors

神经内分泌肿瘤的关键更新: 第9版美国胃肠胰神经内分泌肿瘤癌症分期系统联合委员会

2024-04-295
OAAI
Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) plus best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2
2024-03-220
PRE
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Fruquintinib与安慰剂在难治性转移性结直肠癌患者中的比较 (FRESCO-2): 一项国际,多中心,随机,双盲,3期研究

LANCET
IF88.5
2023-07-01101
PRE
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

2021国家癌症研究所神经内分泌肿瘤临床试验计划会议共识报告

2023-05-311
OA
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

北美神经内分泌肿瘤学会关于高级别胃肠胰和妇科神经内分泌肿瘤管理的专家共识实践建议

2023-05-1518
OAAI
Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours- A systematic review and meta-analysis

神经内分泌肿瘤患者抗血管内皮生长受体酪氨酸激酶抑制剂的疗效和毒性-系统评价和meta分析

2023-03-013
OAAI
Survival improvement for patients with metastatic colorectal cancer over twenty years
2023-02-1359
OAAI
Phase II study of durvalumab anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
2022-08-2527
OAAI
Magnetic Resonance Imaging Directed Surgical Decision Making for Lateral Pelvic Lymph Node Dissection in Rectal Cancer After Total Neoadjuvant Therapy (TNT)

全新辅助治疗 (TNT) 后直肠癌盆腔侧淋巴结清扫的磁共振成像指导手术决策

2022-07-1524
OA